<div id="readability-page-1"><p>RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech yesterday and set a price target of $74.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Timashev is a 5-star analyst with an average return of <span>31.7%</span> and a 58.00% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Exelixis, and Jazz Pharmaceuticals.</p> <p>In addition to RBC Capital, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued on November 26. However, on November 21, TR | OpenAI – 4o reiterated a Hold rating on Legend Biotech (NASDAQ: LEGN).</p></div>

LEGN

<p>RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech with a price target of $74.00. Timashev, a 5-star analyst, has an average return of 31.7% and a 58% success rate. Legend Biotech also received a Buy rating from H.C. Wainwright's Mitchell Kapoor, while TR | OpenAI reiterated a Hold rating on November 21.</p>

RBC Capital Remains a Buy on Legend Biotech (LEGN)